Medtronic Taps New Ablation Chief as FDA Clears Sinus Blades and Barclays Starts at Equal-Weight

Medtronic appoints Felicia Kurz to lead cardiac ablation as it converts FDA and CE clearances into commercial sales; Barclays starts MDT at Equal-Weight, $95 target.

Medtronic has reshuffled leadership in one of its most closely watched franchises, naming Felicia Kurz as Vice President and General Manager of its cardiac ablation solutions business. The appointment lands just as the medtech group converts a cluster of regulatory wins into commercial ambitions, and it puts a fresh executive in charge of proving that newly cleared hardware and software can win over hospital procurement committees.

The regulatory run began around the turn of the month. Medtronic secured both FDA clearance and European CE marking for its Affera Prism-2 mapping software, and separately picked up CE marking for the PulseSelect ProxBox adapter with Proximity Indicator software. Days later, the company added a 510(k) clearance from the FDA for its ApexCut EM navigation blades, a powered instrument set built for sinus surgery and designed to run with Medtronic's own Stealth AXiS ENT system.

That ENT clearance carries a condition. The blades pair powered surgical tools directly with navigation technology, but the first U.S. patient cases — targeted for 2026 — hinge on an updated version of the navigation software reaching the field before surgeons can use them.

A pipeline of clearances, and a question of speed

For investors, the flurry of approvals matters less as a headline than as a test of execution. Clearance is a necessary condition for adoption, not a guarantee of it. Hospitals weighing new capital purchases want dependable workflows and demonstrable efficiency gains, and the Affera Prism-2 software must prove itself against entrenched competitors inside the electrophysiology lab.

Management's to-do list is therefore operational: tighten sales structures and accelerate training programs for electrophysiologists. Whether cardiac ablation becomes a genuine growth engine will be settled by unit sales over the coming quarters, not by the certificates themselves.

The bull case runs through smooth rollout. Rapid uptake of Affera Prism-2 and the PulseSelect accessories across the U.S. and Europe would sharpen Medtronic's technological edge, and hospitals could gain shorter procedure times from combining advanced mapping with targeted ablation — a combination that ought to loosen purse strings.

Billing codes add a second layer of support

Broader reimbursement momentum reinforces that story. Roughly a week ago, the American Medical Association granted permanent Category-I CPT codes for Medtronic's Altaviva implant and its Symplicity Spyral system, effective January 2028. Such codes matter because they lock in insurer reimbursement and smooth the path to wider hospital use, giving procedures for hypertension and urge incontinence long-term financial predictability.

The risk side is equally concrete. If installation of the new mapping software stalls at leading heart centers, or if staff training drags, market share can slip away — the cardiac intervention arena is fiercely contested and rivals defend their installed bases aggressively. Should the new cardiology systems meet reluctance from hospital purchasing departments, development spending could start to weigh on margins.

Structural pressures in healthcare persist as well, from cost containment across health systems to staffing shortages in cardiology units. If measurable ablation revenue undershoots expectations, valuation pressure could build.

Wall Street takes a measured view

Barclays stepped into the story on the same day as the ENT clearance. Analyst Christopher Pasquale initiated coverage of Medtronic stock, ticker MDT, with an Equal-Weight rating and a price target of $95. The neutral stance implies the firm sees near-term upside roughly in line with the broader market, even as the company expands its product lines — a sign that medtech watchers are weighing the pipeline against execution risk.

Trading has been subdued. In European dealings the shares edged up 0.08% to EUR 77.42 following the ApexCut news, while the prior Wednesday's close came in at EUR 76.56, a daily decline of 1.0%. Market capitalization stands at EUR 99.52 billion, or roughly EUR 99.96 billion on the later reading.

MiniMed exchange remains the next catalyst

Away from the operating businesses, Medtronic still intends to exchange its remaining 27,452,053 MiniMed shares in the event of oversubscription, completing the accounting and strategic separation of the diabetes unit. That transaction is the next hard catalyst on the calendar.

So long as the company converts regulatory clearances into actual shipments and the ablation realignment proceeds without friction, the structural foundation holds. Let operational momentum in the cardiology launches falter, and the growth outlook dims accordingly.